ADAMTS13: A disintegrin and metalloproteinase with thrombospondin motifs 13
Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. .
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ADAMTS13, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Apadamtase alfa | Approved | Takeda Pharmaceuticals USA | Protein or peptide | Exogenous proteinA disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein | 4 |
| A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program | Apadamtase alfa | — | Recruiting | Takeda | Feb 24, 2026 |
| A Study of TAK-755 in Adults With Acute Ischemic Stroke | Apadamtase alfa | Phase 2 | Recruiting | Takeda | Feb 6, 2026 |
| A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | Apadamtase alfa | — | Recruiting | Takeda | Jun 4, 2024 |
| A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | Apadamtase alfa | Phase 3 | Active, not recruiting | Takeda | Dec 24, 2020 |
- Congenital thrombotic thrombocytopenic purpura0.86
- Thrombotic thrombocytopenic purpura0.70
- Thrombocytopenia0.38
- Abnormal bleeding0.36
- Atypical hemolytic-uremic syndrome0.31
- Hereditary disease0.20
- Thrombotic disease0.16
- COVID-190.12
- Hepatocellular carcinoma0.11
- Stroke disorder0.11
- Diabetes mellitus0.10
- Deep vein thrombosis0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2346492, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q76LX8, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets